The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis

被引:25
|
作者
Kumar, Virender [1 ]
Dong, Yuxiang [1 ]
Kumar, Vinod [1 ]
Almawash, Saud [1 ]
Mahato, Ram I. [1 ]
机构
[1] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, 986025 Nebraska Med Ctr, Omaha, NE 68198 USA
来源
THERANOSTICS | 2019年 / 9卷 / 25期
关键词
Liver fibrosis; Hedgehog; MDB5; GDC-0449; HEPATIC STELLATE CELLS; POLYMERIC MICELLES; OSTEOPONTIN; BIODISTRIBUTION; ACTIVATION; EXPRESSION; MIRNA; YAP; PHARMACOKINETICS; MATRIX;
D O I
10.7150/thno.38913
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rationale: Hedgehog (Hh) pathway plays an essential role in liver fibrosis by promoting the proliferation of hepatic stellate cells (HSCs) by enhancing their metabolism via yes-associated protein 1 (YAP1). Despite the presence of several inhibitors, Hh signaling cannot be controlled exclusively due to their poor efficacy and the lack of a suitable delivery system to the injury site. Therefore, it is rationale to develop new potent Hh inhibitors and suitable delivery carriers. Methods: Based on the structure and activity of Hh inhibitor GDC-0449, we replaced its sulfonamide group with two methylpyridine-2yl at amide nitrogen to synthesize MDB5. We compared the Hh pathway inhibition and anti-fibrotic effect of MDB5 with GDC-0449 in vitro. Next, we developed MDB5 loaded micelles using our methoxy poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol (PEG-PCC-g-DC) copolymer and characterized for physicochemical properties. We evaluated the therapeutic efficacy of MDB5 loaded micelles in common bile duct ligation (CBDL) induced liver fibrosis, mouse model. We also determined the intrahepatic distribution of fluorescently labeled micelles after MDB5 treatment. Results: Our results show that MDB5 was more potent in inhibiting Hh pathway components and HSC proliferation in vitro. We successfully developed MDB5 loaded micelles with particle size of 40 +/- 10 nm and drug loading up to 10% w/w. MDB5 loaded micelles at the dose of 10 mg/kg were well tolerated by mice, without visible sign of toxicity. The serum enzyme activities elevated by CBDL was significantly decreased by MDB5 loaded micelles compared to GDC-0449 loaded micelles. MDB5 loaded micelles further decreased collagen deposition, HSC activation, and Hh activity and its target genes in the liver. MDB5 loaded micelles also prevented liver sinusoidal endothelial capillarization (LSEC) and therefore restored perfusion between blood and liver cells. Conclusions: Our study provides evidence that MDB5 was more potent in inhibiting Hh pathway in HSC-T6 cells and showed better hepatoprotection in CBDL mice compared to GDC-0449.
引用
收藏
页码:7537 / 7555
页数:19
相关论文
共 50 条
  • [21] Brief Report: Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449.
    Rudin, Charles M.
    Hann, Christine L.
    Laterra, John
    Yauch, Robert L.
    Callahan, Christopher A.
    Fu, Ling
    Holcomb, Thomas
    Stinson, Jeremy
    Gould, Stephen E.
    Coleman, Barbara
    LoRusso, Patricia M.
    Von Hoff, Daniel D.
    de Sauvage, Frederic J.
    Low, Jennifer A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12): : 1173 - 1178
  • [22] Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma-induced liver fibrosis
    Elhenawy, Abeer A.
    Ashour, Rehab H.
    Nabih, Nairmen
    Shalaby, Naglaa M.
    Megahed, Nirmeen
    PARASITOLOGY INTERNATIONAL, 2017, 66 (05) : 545 - 554
  • [23] Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer
    Lee, Dae-Hee
    Lee, Suk-young
    Oh, Sang Cheul
    TUMOR BIOLOGY, 2017, 39 (06)
  • [24] Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride-induced liver fibrosis in rats
    El-Agroudy, Nermeen N.
    El-Naga, Reemn
    Abd El-Razeq, Rania
    El-Demerdash, Ebtehal
    BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (22) : 3248 - 3260
  • [25] Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma
    Kelleher, Fergal C.
    Cain, Jason E.
    Healy, Joan M.
    Watkins, D. Neil
    Thomas, David M.
    PHARMACOLOGY & THERAPEUTICS, 2012, 136 (02) : 153 - 168
  • [26] The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers
    Doggrell, Sheila A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (03) : 451 - 454
  • [27] Quercetin ameliorates liver fibrosis in Wilson disease and EMT involving suppression of the Hedgehog signaling pathway
    Chen, Jie
    Yang, Wenming
    Dong, Ting
    Chen, Huaizhen
    Zhang, Jing
    Xu, Guocun
    Zhao, Chenling
    Zeng, Jingyu
    Tang, Lulu
    ARABIAN JOURNAL OF CHEMISTRY, 2024, 17 (01)
  • [28] A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib
    Baur, Vera
    Papadopoulos, Thomas
    Kazakov, Dmitry, V
    Agaimy, Abbas
    Hartmann, Arndt
    Isbary, Georg
    Wirtz, Ralph M.
    Schultz, Erwin S.
    VIRCHOWS ARCHIV, 2018, 473 (02) : 241 - 246
  • [29] A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib
    Vera Baur
    Thomas Papadopoulos
    Dmitry V. Kazakov
    Abbas Agaimy
    Arndt Hartmann
    Georg Isbary
    Ralph M. Wirtz
    Erwin S. Schultz
    Virchows Archiv, 2018, 473 : 241 - 246
  • [30] Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis
    Grizzi, Fabio
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2009, 36 (10) : 961 - 962